George J Weiner

List of Publications by Year
in descending order

146 papers	10,159 citations	34105 52 h-index	36028 97 g-index
150 all docs	150 docs citations	150 times ranked	13354 citing authors

#	Article	IF	Citations
1	Rituximab: Mechanism of Action. Seminars in Hematology, 2010, 47, 115-123.	3.4	629
2	CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9305-9310.	7.1	569
3	Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 2015, 15, 361-370.	28.4	558
4	Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10833-10837.	7.1	479
5	Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology, 2011, 29, 4828-4836.	1.6	411
6	Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy, 2010, 33, 335-351.	2.4	293
7	Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.. Journal of Clinical Oncology, 1997, 15, 1143-1149.	1.6	280
8	Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. Cancer Research, 2015, 75, 5-10.	0.9	261
9	Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs. Journal of Immunology, 2001, 167, 4878-4886.	0.8	221
10	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood, 2006, 108, 2648-2654.	1.4	215
11	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. Blood, 1997, 89, 2994-2998.	1.4	184
12	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 4191-4198.	1.6	184
13	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180
14	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	21.4	179
15	NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood, 2008, 111, 1456-1463.	1.4	172
16	Bispecific antibodies in cancer therapy. Current Opinion in Immunology, 1999, 11, 558-562.	5.5	159
17	Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood, 2010, 115, 1156-1165.	1.4	150
18	A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 6697-6703.	7.0	149

#	Article	IF	Citations
19	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
20	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2006, 29, 558-568.	2.4	145
21	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2014, 32, 3506-3512.	1.6	144
22	B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood, 2006, 108, 2712-2719.	1.4	130
23	Radioimmunoscintigraphy with 111 Indium Labeled Cyt-356 for the Detection of Occult Prostate Cancer Recurrence. Journal of Urology, 1994, 152, 1490-1495.	0.4	129
24	Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood, 2009, 114, 5322-5330.	1.4	129
25	Active choice but not too active: Public perspectives on biobank consent models. Genetics in Medicine, 2011, 13, 821-831.	2.4	127
26	CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. Journal of Immunological Methods, 2005, 304, 88-99.	1.4	120
27	CpG oligodeoxynucleotides as immunotherapy in cancer. Update on Cancer Therapeutics, 2008, 3, 27-32.	0.4	120
28	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 1998, 92, 3730-3736.	1.4	119
29	B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides. Clinical Cancer Research, 2005, 11, 1490-1499.	7.0	118
30	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood, 2011, 118, 3347-3349.	1.4	117
31	Monoclonal antibody mechanisms of action in cancer. Immunologic Research, 2007, 39, 271-278.	2.9	112
32	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Nonâ€“Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 6168-6174.	7.0	111
33	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, 2011, 117, 1492-1498.	1.4	110
34	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
35	Complement in monoclonal antibody therapy of cancer. Immunologic Research, 2014, 59, 203-210.	2.9	94
36	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94

#	Article	IF	Citations
37	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. Journal of Clinical Oncology, 2018, 36, 1603-1610.	1.6	93
38	Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Current Opinion in Hematology, 2000, 7, 168-173.	2.5	91
39	Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia, 2003, 17, 314-318.	7.2	90
40	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. Journal of Leukocyte Biology, 2005, 77, 378-387.	3.3	90
41	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 211-217.	1.3	82
42	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discovery, 2021, 11, 2998-3007.	9.4	80
43	Potent Antigen-specific Immune Responses Stimulated by Codelivery of CpG ODN and Antigens in Degradable Microparticles. Journal of Immunotherapy, 2007, 30, 469-478.	2.4	78
44	CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Research, 2003, 63, 5595-600.	0.9	78
45	APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells. Journal of Immunology, 2000, 165, 6244-6251.	0.8	77
46	Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opinion on Biological Therapy, 2008, 8, 759-768.	3.1	76
47	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
48	The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. Journal of Leukocyte Biology, 2000, 68, 455-63.	3.3	63
49	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leukemia and Lymphoma, 2013, 54, 2500-2505.	1.3	58
50	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
51	Biodegradable Microparticles Loaded with Doxorubicin and CpG ODN for In Situ Immunization Against Cancer. AAPS Journal, 2015, 17, 184-193.	4.4	58
52	Humanization and characterization of the anti-HLA-DR antibody 1D10. International Journal of Cancer, 2001, 93, 556-565.	5.1	57
53	A comparative study of the antigenâ€specific immune response induced by coâ€delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles**Xueâ€Qing Zhang and Christopher E. Dahle contributed equally to this work.. Journal of Pharmaceutical Sciences, 2007, 96, 3283-3292.	3.3	57
54	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology, 2017, 46, 1753-1754i.	1.9	57

#	Article	IF	Citations
55	AACR Cancer Progress Report 2013. Clinical Cancer Research, 2013, 19, S1-S98.	7.0	55
56	AACR Cancer Progress Report 2014. Clinical Cancer Research, 2014, 20, S1-S112.	7.0	48
57	CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Current Opinion in Oncology, 2003, 15, 440-445.	2.4	45
58	Obesity diminishes response to PD-1-based immunotherapies in renal cancer. , 2020, 8, e000725.		45
59	CpG Oligodeoxynucleotides Enhance Monoclonal Antibody Therapy of a Murine Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 57-61.	2.1	39
60	CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Advanced Drug Delivery Reviews, 2009, 61, 263-267.	13.7	39
61	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, 118, 4882-4889.	1.4	37
62	Antibody Opsonization of a TLR9 Agonistâ€“Containing Virus-like Particle Enhances In Situ Immunization. Journal of Immunology, 2020, 204, 1386-1394.	0.8	37
63	Germline variation in complement genes and eventâ€free survival in follicular and diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2012, 87, 880-885.	4.1	36
64	Elevated soluble <scp>IL</scp>â€2<scp>R</scp>Î±, <scp>IL</scp>â€8, and <scp>MIP</scp>â€1Î² levels are associated with inferior outcome and are independent of <scp>MIPI</scp> score in patients with mantle cell lymphoma. American Journal of Hematology, 2014, 89, E223-7.	4.1	36
65	Introduction: bispecific antibodies. Journal of Immunological Methods, 2001, 248, 1-6.	1.4	34
66	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed Bâ€cell nonâ€Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 589-593.	4.1	33
67	The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics, 2006, 58, 1-8.	2.4	32
68	Manipulation of cellular redox parameters for improving therapeutic responses in Bâ€cell lymphoma and multiple myeloma. Journal of Cellular Biochemistry, 2012, 113, 419-425.	2.6	32
69	Chemoimmunotherapy for relapsed/refractory and progressive 17p13â€deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and lowâ€dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology, 2014, 89, 757-765.	4.1	32
70	In situimmunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. , 2020, 8, e000940.		31
71	Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 2003, 52, 317-327.	4.2	29
72	Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Seminars in Oncology, 2003, 30, 476-482.	2.2	28

#	Article	IF	Citations
73	Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia, 2003, 17, 1357-1365.	7.2	28
74	CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunology, Immunotherapy, 2006, 55, 515-527.	4.2	28
75	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology, 2011, 86, 998-1000.	4.1	28
76	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunology, Immunotherapy, 2013, 62, 1475-1484.	4.2	28
77	Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. , 1998, 77, 251-256.		27
78	Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia, 2005, 19, 759-766.	7.2	27
79	Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer Journal, 2017, 7, e595-e595.	6.2	27
80	Acute Promyelocytic Infiltration of the Optic Nerve Treated by Oral Trans-retinoic Acid. Ophthalmology, 1992, 99, 1463-1467.	5.2	26
81	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2015, 33, 3930-3937.	1.6	24
82	Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy. Leukemia and Lymphoma, 1995, 16, 199-207.	1.3	22
83	Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer. Annals of Surgical Oncology, 2021, 28, 1187-1197.	1.5	21
84	Monoclonal antibody therapy of B cell lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 375-385.	3.1	20
85	Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leukemia and Lymphoma, 2015, 56, 2373-2378.	1.3	20
86	CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Advanced Drug Delivery Reviews, 2009, 61, 193-194.	13.7	19
87	Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Seminars in Oncology, 2002, 29, 93-97.	2.2	18
88	Picking the Optimal Target for Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e103-e107.	3.8	18
89	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica, 2018, 103, 297-303.	3.5	17
90	Intestinal Helminths Regulate Lethal Acute Graft-versus-Host Disease and Preserve the Graft-versus-Tumor Effect in Mice. Journal of Immunology, 2015, 194, 1011-1020.	0.8	16

#	Article	IF	Citations
91	Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. , 2021, 9, e002484.		16
92	CpG oligodeoxynucleotides enhance FcÂRI-mediated cross presentation by dendritic cells. International Immunology, 2004, 16, 1091-1098.	4.0	15
93	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. ACS Biomaterials Science and Engineering, 2020, 6, 2659-2667.	5.2	15
94	Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. Leukemia and Lymphoma, 1998, 31, 237-249.	1.3	14
95	Immunostimulatory DNA sequences and cancer therapy. Seminars in Immunopathology, 2000, 22, 107-116.	4.0	14
96	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leukemia and Lymphoma, 2015, 56, 434-439.	1.3	14
97	B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. International Immunology, 2014, 26, 383-395.	4.0	13
98	Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach. Cancer Immunology Research, 2015, 3, 389-398.	3.4	13
99	Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. PLoS ONE, 2013, 8, e76889.	2.5	13
100	Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. Journal of Hematology and Oncology, 2021, 14, 204.	17.0	13
101	Immunoscintigraphy with111 In-satumomab pendetide in patients with colorectal adenocarcinoma:. Diseases of the Colon and Rectum, 1994, 37, 129-137.	1.3	12
102	The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379). Nuclear Medicine and Biology, 1994, 21, 131-142.	0.6	12
103	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clinical Cancer Research, 2017, 23, 954-961.	7.0	12
104	Minimally differentiated acute leukemia. Leukemia Research, 1993, 17, 199-208.	0.8	11
105	The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility. Leukemia, 2007, 21, 2354-2355.	7.2	10
106	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.9	10
107	O85â€...Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. , 2020, 8, A2.2-A3.		10
108	T Cell Activation and Cytokine Production in Anti-CD3 Bispecific Antibody Therapy. Stem Cells and Development, 1995, 4, 395-402.	1.0	9

#	Article	IF	Citations
109	Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. Journal of Immunological Methods, 2005, 297, 259-263.	1.4	9
110	Helminth-Induced Production of TGF-Î² and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. Journal of Immunology, 2018, 201, 2910-2922.	0.8	9
111	A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors. Cancer Immunology Research, 2020, 8, 1206-1214.	3.4	9
112	Antibody Therapy of Lymphoma. Advances in Pharmacology, 2004, 51, 229-253.	2.0	8
113	304â€...Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. , 2020, , .		8
114	Expression of both B7â€1 and CD28 contributes to the ILâ€2 responsiveness of CTLLâ€2 cells. Immunology, 1996, 87, 271-274.	4.4	7
115	T cells, particularly activated CD4+ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. Cancer Immunology, Immunotherapy, 2022, 71, 237-249.	4.2	7
116	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. Blood, 2006, 108, 530-530.	1.4	6
117	Radiolabeled Antibody Imaging of Patients with Potentially Resectable Colorectal Adenocarcinoma. Cancer Investigation, 1994, 12, 111-120.	1.3	5
118	5E10: a prostate-specific surface-reactive monoclonal antibody. Cancer Letters, 1998, 131, 129-136.	7.2	5
119	An RNA Aptamerâ€"Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer Immunology Research, 2019, 7, 1511-1522.	3.4	5
120	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	1.4	5
121	Short telomeres in B-CLL: the chicken or the egg?. Blood, 2008, 111, 5756-5756.	1.4	4
122	The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Scientific Reports, 2021, 11, 1535.	3.3	4
123	T-cell activation induced by anti-CD3 Ã— anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand. Cancer Immunology, Immunotherapy, 1997, 45, 174-179.	4.2	3
124	Measuring Granulocyte and Monocyte Accumulation at Malignant Lymphoma Sites. Journal of Clinical Oncology, 2009, 27, 154-155.	1.6	3
125	Serum Alters the Uptake and Biologic Activity of CpG Oligodeoxynucleotides in B Cell Chronic Lymphocytic Leukemia. Oligonucleotides, 2005, 15, 51-59.	2.7	2
126	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Leukemia and Lymphoma, 2015, 56, 2365-2372.	1.3	2

#	Article	IF	Citations
127	Immune checkpoint markers and antiâ€CD20â€mediated NK cell activation. Journal of Leukocyte Biology, 2020, 110, 723-733.	3.3	2
128	Activation of NK Cell Responses and Immunotherapy of Cancer. , 2014, , 57-66.		2
129	Persistent thrombocytopenia during remission in acute leukemia does not preclude long-term disease-free survival. American Journal of Hematology, 2002, 71, 236-237.	4.1	1
130	Making a better antibody: all is not lost. Blood, 2010, 115, 5127-5128.	1.4	1
131	Brachytherapy Combined with CpG ODN Enhances Development of a Tumor Antigen-Specific CD8 Response.. Blood, 2004, 104, 4635-4635.	1.4	1
132	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	1.4	1
133	In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.. Blood, 2005, 106, 4826-4826.	1.4	1
134	Commentary on â€œThe History of the Development of Vaccines for the Treatment of Lymphomaâ€. Clinical Lymphoma and Myeloma, 2000, 1, 140.	2.1	0
135	Cancer biology: Lost in translation?. Cancer Biology and Therapy, 2004, 3, 688-691.	3.4	0
136	Response: Complement in antibody therapy for lymphoma: both a help and a hindrance?. Blood, 2009, 114, 5568-5568.	1.4	0
137	No Mechanism is an Island. , 2014, , 257-267.		0
138	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	3.7	0
139	Quantification of Receptor Occupancy by Ligandâ€”An Understudied Class of Potential Biomarkers. Cancers, 2020, 12, 2956.	3.7	0
140	Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod. Vaccines, 2021, 9, 982.	4.4	0
141	Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.. Blood, 2004, 104, 4828-4828.	1.4	0
142	IL-21 and CpG ODN Are Synergistic in Their Ability To Induce Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells and Benign B1 Cells.. Blood, 2005, 106, 5022-5022.	1.4	0
143	IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.. Blood, 2006, 108, 2823-2823.	1.4	0
144	Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T Cell Expansion.. Blood, 2009, 114, 2674-2674.	1.4	0

#	Article	IF	Citations
145	Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better. Transactions of the American Clinical and Climatological Association, 2015, 126, 87-92.	0.5	0
146	Advances in the management of B-cell lymphomas. Clinical Advances in Hematology and Oncology, 2007, 5, 510-2.	0.3	0